Circulating Insulin-like Growth Factor-1 and Risk of Lung Diseases: A Mendelian Randomization Analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Mar 20

PMID 36936149

Authors

Sujing Jiang

Zhiyong Xu

Yueli Shi

Sibei Liang

Xinyuan Jiang

Mingshu Xiao

Kai Wang

Liren Ding

Affiliations

Soon will be listed here.

Abstract

Background: Insulin-like growth factor-1 (IGF-1) display a vital role in in the pathogenesis of lung diseases, however, the relationship between circulating IGF-1 and lung disease remains unclear.

Methods: Single nucleotide polymorphisms (SNPs) associated with the serum levels of IGF-1 and the outcomes data of lung diseases including asthma, chronic obstructive pulmonary disease (COPD), lung cancer and idiopathic pulmonary fibrosis (IPF) were screened from the public genome-wide association studies (GWAS). Two-sample Mendelian randomization (MR) analysis was then performed to assess the independent impact of IGF-1 exposure on these lung diseases.

Results: Totally, 416 SNPs related to circulating IGF-1 levels among 358,072 participants in UK Biobank. According to a primary casual effects model with MR analyses by the inverse variance weighted (IVW) method, the circulating IGF-1 was demonstrated a significantly related with the risk of asthma (OR, 0.992; 95% CI, 0.985-0.999, =0.0324), while circulating IGF-1 showed no significant correlation with CODP (OR, 1.000; 95% CI, 0.999-1.001, =0.758), lung cancer (OR, 0.979, 95% CI, 0.849-1.129, =0.773), as well as IPIGFF (OR, 1.100, 95% CI, 0.794-1.525, =0.568).

Conclusion: The present study demonstrated that circulating IGF-1 may be causally related to lower risk of asthma.

Citing Articles

What is the role of nonalcoholic fatty liver disease in pulmonary carcinoma development?.

Pan Q, Xu Q, Zhang L, He Y World J Gastroenterol. 2025; 31(5):97500.

PMID: 39926215 PMC: 11718604. DOI: 10.3748/wjg.v31.i5.97500.

The Phytochemical Profile of the Petroleum Ether Extract of Leaves and Its Anticancer Effect on 4-(Methylnitrosamino)-1-(3-pyridyl)-1-buta-4 None (NNK)-Induced Lung Cancer in Rats.

Abd Elkarim A, Mohamed S, Ali N, Elsayed G, Aly M, Elgamal A Int J Mol Sci. 2024; 25(23).

PMID: 39684736 PMC: 11641252. DOI: 10.3390/ijms252313024.

Exercise's impact on lung cancer molecular mechanisms: a current overview.

Mancini A, Orlandella F, Vitucci D, Luciano N, Alfieri A, Orru S Front Oncol. 2024; 14:1479454.

PMID: 39555455 PMC: 11563951. DOI: 10.3389/fonc.2024.1479454.

Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.

Chen Y, Cao S, Shao S, Tong Z BMC Pulm Med. 2024; 24(1):488.

PMID: 39375737 PMC: 11459707. DOI: 10.1186/s12890-024-03289-y.

Highlights on Future Treatments of IPF: Clues and Pitfalls.

Libra A, Sciacca E, Muscato G, Sambataro G, Spicuzza L, Vancheri C Int J Mol Sci. 2024; 25(15).

PMID: 39125962 PMC: 11313529. DOI: 10.3390/ijms25158392.

References

Pala L, Giannini S, Rosi E, Cresci B, Scano G, Mohan S . Direct measurement of IGF-I and IGFBP-3 in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis. J Endocrinol Invest. 2002; 24(11):856-64. DOI: 10.1007/BF03343942. View

Mu M, Wu F, He J, Tang X, Ma H, Guo S . Insulin‑like growth factor 1 inhibits phagocytosis of alveolar epithelial cells in asthmatic mice. Mol Med Rep. 2019; 20(3):2381-2388. DOI: 10.3892/mmr.2019.10456. View

Krein P, Winston B . Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. Chest. 2002; 122(6 Suppl):289S-293S. DOI: 10.1378/chest.122.6_suppl.289s. View

Kawaguchi M, Fujita J, Kokubu F, Ohara G, Huang S, Matsukura S . Induction of insulin-like growth factor-I by interleukin-17F in bronchial epithelial cells. Clin Exp Allergy. 2010; 40(7):1036-43. DOI: 10.1111/j.1365-2222.2010.03527.x. View

Burgess S, Bowden J, Fall T, Ingelsson E, Thompson S . Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants. Epidemiology. 2016; 28(1):30-42. PMC: 5133381. DOI: 10.1097/EDE.0000000000000559. View

Le Roith D, BONDY C, Yakar S, Liu J, Butler A . The somatomedin hypothesis: 2001. Endocr Rev. 2001; 22(1):53-74. DOI: 10.1210/edrv.22.1.0419. View

Devesa J, Almenglo C, Devesa P . Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?. Clin Med Insights Endocrinol Diabetes. 2016; 9():47-71. PMC: 5063841. DOI: 10.4137/CMED.S38201. View

Gapstur S, Kopp P, Chiu B, Gann P, Colangelo L, Liu K . Longitudinal associations of age, anthropometric and lifestyle factors with serum total insulin-like growth factor-I and IGF binding protein-3 levels in Black and White men: the CARDIA Male Hormone Study. Cancer Epidemiol Biomarkers Prev. 2004; 13(12):2208-16. View

Bloor C, Knight R, Kedia R, Spiteri M, Allen J . Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med. 2001; 164(2):265-72. DOI: 10.1164/ajrccm.164.2.2003114. View

10.

Larsson S, Carter P, Vithayathil M, Kar S, Mason A, Burgess S . Insulin-like growth factor-1 and site-specific cancers: A Mendelian randomization study. Cancer Med. 2020; 9(18):6836-6842. PMC: 7520358. DOI: 10.1002/cam4.3345. View

11.

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J . UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015; 12(3):e1001779. PMC: 4380465. DOI: 10.1371/journal.pmed.1001779. View

12.

Jensen-Cody S, Potthoff M . Hepatokines and metabolism: Deciphering communication from the liver. Mol Metab. 2020; 44:101138. PMC: 7788242. DOI: 10.1016/j.molmet.2020.101138. View

13.

Acat M, Toru Erbay U, Sahin S, Arik O, Ayada C . High serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patients. Bratisl Lek Listy. 2017; 118(11):691-694. DOI: 10.4149/BLL_2017_130. View

14.

Kim W, Jin Q, Oh S, Kim E, Yang Y, Lee D . Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009; 69(18):7439-48. PMC: 2745504. DOI: 10.1158/0008-5472.CAN-08-3792. View

15.

Burgess S, Thompson S . Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017; 32(5):377-389. PMC: 5506233. DOI: 10.1007/s10654-017-0255-x. View

16.

Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa T . Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med. 1995; 152(6 Pt 1):2084-9. DOI: 10.1164/ajrccm.152.6.8520779. View

17.

Davey Smith G, Ebrahim S . 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?. Int J Epidemiol. 2003; 32(1):1-22. DOI: 10.1093/ije/dyg070. View

18.

Wang Y, Hailey J, Williams D, Wang Y, Lipari P, Malkowski M . Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther. 2005; 4(8):1214-21. DOI: 10.1158/1535-7163.MCT-05-0048. View

19.

Guix M, Faber A, Wang S, Olivares M, Song Y, Qu S . Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008; 118(7):2609-19. PMC: 2430495. DOI: 10.1172/JCI34588. View

20.

Heemskerk V, Daemen M, Buurman W . Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev. 1999; 10(1):5-14. DOI: 10.1016/s1359-6101(98)00022-7. View